Bristol agrees to ADAP discounts
Bristol agrees to provide additional aid to state AIDS Drug Assistance programs by offering them "its entire portfolio of HIV medications at a reduced cost" through March 31, 2005. Bristol is the last of eight HIV drug manufacturers to reach an agreement with the ADAP coalition (1"The Pink Sheet" July 14, 2003, In Brief)....1
You may also be interested in...
Pfizer, GlaxoSmithKline and Boehringer-Ingelheim agree to provide additional aid to AIDS Drug Assistance Programs. GSK will offer a "$20 mil. financial aid package" to ADAPs to help cut waiting lists and avoid program restrictions, company says. Pfizer is offering its antiretroviral drugs Viracept and Rescriptor "either free or at greatly discounted prices" and will "maintain price neutrality" on its new 625 mg Viracept formulation compared to older formulations, Pfizer says. Negotiations with Bristol-Myers Squibb continue (1"The Pink Sheet" May 19, 2003, In Brief)...
A lack of regulatory harmonization for dietary supplements in Asia is a big challenge facing companies operating in the region, according to experts from the Asia Regulatory Professionals Association. The ARPA is looking to start a conversation on the issue which the association hopes will lead to regulatory change.
The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.